Introduction

History and Epidemiology
History
NSIP began to gain attention in 1994 when Katzenstein and Fiorelli 3 described histologic findings that did not fit the traditional Liebow classification of interstitial pneumonia. These pathology showed temporally uniform inflammation and fibrosis which distinguished them from other interstitial pneumonias, such as usual interstitial pneumonia (UIP). However, authors at the time concluded that it would be unreasonable to regard NSIP as an independent disease entity. In subsequent studies, the possibility was raised that NSIP might be independent disease entity although the histologic findings of NSIP were associated with a variety of causes including connective tissue disease (CTD) 2 . And, at the 2002 American Thoracic Society (ATS)/European Respiratory Society (ERS) international consensus classification, NSIP was classified as "provisional type" interstitial pneumonia 4 . In 2008, Travis et al. 2 reported that idiopathic NSIP is a distinct clinical entity that is distinguishable from other interstitial pneumonias. They also reported that NSIP occurred mostly in non-smoking middle aged women, and its prognosis is good. In the recent revised ATS/ERS international consensus classification, idiopathic NSIP was classified as a distinct entity among the IIPs 1 .
Epidemiology
The incidence and prevalence of NSIP are not clearly known. However, according to several retrospective cohort studies, the prevalence has been estimated at 1 to 9 per 100,000 people 5 , and the incidence has been estimated at around 3 per one million people 6 . According to a nationwide survey conducted by the Korean Academy and Tuberculosis and Respiratory Diseases in 2008, NSIP was the second common IIP next to idiopathic pulmonary fibrosis (IPF), accounting for 11.9% of 2,186 patients with IIP 7 . In a recent cohort of a university hospital in Denmark, 431 cases of interstitial lung diseases were analyzed from 2003 to 2009. NSIP accounted for 7% of them. And it was the fourth most common interstitial lung disease following IPF, CTD interstitial pneumonia, and hypersensitivity pneumonitis (HP) 6 . NSIP is more common in females and non-smokers than their counterparts, and occurs at lower ages than IPF 2, 7 .
Clinical Features and Diagnosis
Clinical features
Clinical manifestations include subacute or chronic dyspnea and cough that last an average of 6 months, most of which occur in non-smoking, middle-aged women. Bilateral end-inspiratory crackles at the base of chest can be heard but most of physical findings are nonspecific. Pulmonary function tests show a restrictive ventilatory defect 2 . Because similar clinical manifestations can occur in the patients with HP, drug toxicities and occupational lung diseases, detailed history taking is necessary to find exposure to specific antigens such as birds, drugs, or occupational exposures. In addition, the NSIP pattern is known to be the most common histologic pattern of pulmonary involvement in various CTDs. Therefore, in order to exclude specific CTDs, it is important to check for symptoms such as Raynaud' s phenomenon, arthralgia or arthritis, skin rash, dry mouth, and dry eye. Autoantibodies, such as anti-nuclear antibody, rheumatoid factor, and anti-cyclic citrullinated peptide, are also useful markers and should be considered for exclude CTDs 8 . However, in many patients, even if autoantibody is positive, clinical manifestations are not sufficient for diagnosis of specific CTD 2, [9] [10] [11] [12] . If the diagnostic criteria of a specific CTD are not met despite autoantibodies or some clinical features are similar to those of CTD, diagnosis as an idiopathic NSIP can be made. Recently, there has been a proposal to use the term "interstitial pneumonia with autoimmune features (IPAF). " IPAF is a term to characterize the heterogenous group of patients with IIPs who have a clinical flavor of underlying CTDs but do not meet the current American College of Rheumatology criteria for CTDs 13 . But, the concepts of IPAF are proposed to provide a platform for the prospective study of these heterogenous group and are not intended as guidelines for clinical care. At present, IPAF will need to be validated via prospective research studies and we should be careful to apply it to real clinical field.
Diagnosis
The diagnosis of NSIP is similar to that of other interstitial pneumonias including IPF, and it is important to diagnose it . The differential diagnosis is summarized in Table 1 .
1) Radiological examination
The common findings in thoracic high-resolution computed tomography (HRCT) in NSIP are bilateral reticular opacities, traction bronchiectasis, reduced volume of the lobes, and ground-glass opacity in the lower lungs 2, [14] [15] [16] . These lesions can involve diffuse bilateral lungs or subpleural area. Although it is not common, 20% of patients showed subpleural sparing which is helpful in distinguishing NSIP from IPF. Unlike UIP, honeycombing is sparse or absent ( Figure 1 ). Consolidation, if present, indicates organizing pneumonia component and may suggest the presence of CTD 2 . Unlike UIP, it is not possible to diagnose NSIP with HRCT findings alone.
2) Bronchoscopy
Although T lymphocyte fractions increase (>20%) in the bronchoalveolar lavage (BAL) fluid of most patients, it is nonspecific finding and only plays an auxiliary role for differential diagnosis. For example, increase of T lymphocyte fractions in www.e-trd.org BAL fluid could also be present in HP. If there is no lymphocytosis in the BAL fluid and the fraction of the neutrophil is high, the possibility of IPF rather than NSIP should be considered 17, 18 . Transbronchial lung biopsy is not recommended for definite diagnosis of NSIP because the size of specimen is insufficient.
3) Lung biopsy
Lung biopsy is essential for definite diagnosis of NSIP. The histologic features of NSIP pattern include diffuse interstitial inflammation and fibrosis which are temporally homogeneous. And, usually the basic structure of the alveoli is preserved ( Figure 2) 2,3
. NSIP pattern can be classified into cellular and fibrotic NSIP. In cellular NSIP, chronic inflammatory cells infiltrate the alveolar wall and fibrosis of the alveolar wall is hardly observed. Fibrotic NSIP is associated with alveolar wall thickening and fibrosis with or without infiltration of inflammatory cells in the alveolar wall 5, 19, 20 . Fibrotic NSIP is more common than cellular NSIP and accounts for 80%-90% of the total NSIP 2,21 . The organizing pneumonia or honeycombing should be sparse or absent. The extent of organizing pneumonia is less than 10% to 20%, even if observed ( Table 2) .
The diagnosis of idiopathic NSIP can be summarized as the following.
( 22 . Because idiopathic NSIP has a low prevalence and has relatively recently been categorized as an independent disease entity, there are no randomized controlled trials that have demonstrated the natural remission rate without treatment or the therapeutic effect of medications. However, previous retrospective studies have reported that steroids and other immunosuppressive agents induce remission or stabilization of symptoms and pulmonary function 23, 24 . Kim et al. 24 reported that among 35 patients with histologically confirmed NSIP who were treated with prednisolone (0.5 mg/kg), 32 patients survived and pulmonary function improved in 24 patients and maintained stable conditions in 6 patients. In study of Watanabe et al. 25 , after 1 year of steroid treatment, all of 10 patients showed improvement in lung function and oxygenation and only one patient died after 4.3 years of follow-up.
However, this treatment strategy with steroids and immunosuppressive agents has its limitation. It is effective when the inflammatory mechanism is predominant, such as cellular NSIP or organizing pneumonia, but ineffective in patients with fibrotic NSIP 26 . Recently, opinions, that anti-fibrotic drugs used in IPF may be helpful in these fibrotic subtypes, has been raised, but further studies are required 22 . There is no clear guideline of dose and duration of steroids, but it is recommended that 0.5 to 1.0 mg/kg or 40 to 60 mg of prednisone can be used as the initial dose. The dose should be maintained for 1 month, and then slowly be reduced 23, 26 . If the disease is severe, high-dose methylprednisolone therapy (1 g/day for 3 days, followed by 1 mg/kg orally, then gradually reduced) may be performed 27, 28 . To make this guideline, the authors attempted a systematic review and meta-analysis of the steroid effect in idiopathic NSIP, but all studies were retrospective and comparative analysis was not possible due to the lack of control group. However, according to Xu et al. 29 , 17 patients (22.9%) died during the 54±34-month follow-up period and 34 patients (45.9%) died during steroid withdrawal in 74 patients with idiopathic NSIP, which proved the effect of steroids. Park et al. 23 reported that the mean duration of steroid treatment in NSIP was 17.4±12.1 months and 36% of the patients experienced recurrence. Kim et al. 24 reported recurrence in six out of 30 steroid-treated patients (20%), which was associated with an initial low dose (0.5 mg/kg) of steroid and short treatment duration.
Immunosuppressive agents include azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil, which are used for steroid sparing or enhancing the steroid effect. There is no consensus on whether these agents should be initiated at the time of diagnosis or the time of disease progression or the occurrence of steroid dependence. In general, these medications are used when there is a dependence on steroids or the need of steroid maintenance for preventing disease recurrence 26, 30 . Among these immunosuppressive agents, cyclophosphamide is the most frequently used. Kondoh et al. 31 conducted a study in which they treated 12 histologically confirmed fibrotic NSIP patients with combination of low-dose steroids (20 mg prednisone, every other day) and cyclophosphamide (1 to 2 mg/kg/day). As a results, 33% showed improvement, 67% (8/12) showed stable response, and 21% had side effects related to cyclophosphamide (hemorrhagic cystitis, leukopenia, myelodysplastic syndrome, and infection) 31 . Corte et al. 32 reviewed 54 patients with rapid progression of NSIP who were treated with IV cyclophosphamide (600 mg/m 2 ) and observed good response in most of the patients after 6 months of treatment. Effects of other drugs such as azathioprine, cyclosporine, and mycophenolate mofetil have been reported in a small number of cases 4 .
On the other hand, literature review was conducted to confirm whether the combination of steroids and immunosuppressive agents is more effective than steroid monotherapy. In a study published by Fujita et al. 10 , 22 patients with idiopathic NSIP were treated (19 with steroids and 3 with steroids and cyclophosphamide), and the mortality rate of patients with combination therapy was 1.5 times (95% confidence interval, 0.26-9.79) that of the patients with steroid monotherapy. However, the study was a small, retrospective study and the patients who were more severe or unresponsive to steroids may have treated with combination therapy. Therefore, the results of this study were needed to be interpreted with caution. Recently, Keir et al. 33 reported the hopeful results with rituximab in 50 patients with severe interstitial lung disease who did not respond to conventional immunosuppressive agents except IPF. In the future, studies on the efficacy of these drugs in idiopathic NSIP need to be conducted.
There is no standardized method for assessing therapeutic response in idiopathic NSIP. However, like IPF, treatment response can be measured by combining the changes of HRCT, symptoms such as dyspnea or cough and pulmonary function test (forced vital capacity [FVC] and carbon monoxide diffusion capacity [DLco] ), usually between 3 and 6 months after the start of treatment 34 . Changes in pulmonary function over time are known to be useful surrogate marker of survival. Reduction of DLco over 15% after 12 months or decrease of FVC over 10% between 6 and 12 months are independently associated with mortality 23, 35, 36 . Therefore, when DLco is reduced over 15% or FVC is reduced over 10% despite treatment without any specific reason such as infection, other treatments such as changing medications or lung transplantation should be considered 37 . In addition to pharmacologic treatment, oxygen therapy for hypoxemia at night or during exercise, treatment for concomitant diseases such as reflux esophagitis Tuberc Respir Dis 2019;82:277-284
www.e-trd.org or pulmonary hypertension, and symptomatic therapy for dyspnea or cough can be performed 38 .
Natural Course and Prognosis
Survival of NSIP is better than IPF 39 . Many studies have reported a 5-year survival rate of more than 70%, and particularly in the case of cellular NSIP, there are few disease-related deaths 2, 7, 23 . Treatment of idiopathic NSIP, although not well proven, is generally begin with steroid only or combined with immunosuppressants such as azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil. The clinical response after the first treatment was generally favorable. About two thirds of patients have improved after initial treatment.
However, frequent recurrences were reported after discontinuation of treatment. Kim et al. 24 reported recurrence in 20% and Park et al. 23 reported recurrence in 36%, and the prognosis of patients with recurrence was worse. In addition, as in the IPF, there may be acute exacerbation during the course of NSIP, and Park et al. 40 reported acute exacerbation of 4.2% for one year in patients with idiopathic NSIP.
NSIP pattern is the most common interstitial pneumonia that occurs in CTDs. Therefore, it has always been suggested that NSIP may be the first or the only manifestation of CTD. The possibility that NSIP could be the first manifestation of CTD was firstly raised by Sato et al. 41 . Kinder et al. 11 reported that 80% of 28 idiopathic NSIPs met the criteria for undifferentiated connective tissue disease (UCTD), and Park et al. 23 reported that eight of 83 patients (10%) initially thought to be idiopathic NSIP were diagnosed with CTD in the process of their illness. In fact, a large number of patients with NSIP currently do not meet the criteria for specific CTD have some features of CTD. The researchers described these patients with other names, such as UCTD-interstitial lung disease, lung-dominant CTD, or autoimmune featured ILD. Recently, ATS/ERS proposed "interstitial pneumonia with autoimmune features (IPAF)" for them 42 . Therefore, patients with histologically NSIP pattern should go through sufficient consideration of the presence of CTD, and the occurrence of CTD should be carefully observed in the following process.
